NasdaqGS - Delayed Quote • USD
BridgeBio Pharma, Inc. (BBIO)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 6:32 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 10 | 10 | 11 |
| Avg. Estimate | -0.89 | -0.9 | -3.27 | -3.06 |
| Low Estimate | -1.08 | -1.1 | -5.21 | -5.14 |
| High Estimate | -0.74 | -0.77 | -1.58 | -1.84 |
| Year Ago EPS | -0.92 | -0.98 | -3.95 | -3.27 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 6 | 7 | 9 |
| Avg. Estimate | 14.03M | 3.86M | 164.24M | 185.55M |
| Low Estimate | -- | -- | 12.9M | 116.1M |
| High Estimate | 52M | 15M | 459.78M | 256.97M |
| Year Ago Sales | 1.83M | -- | 9.3M | 164.24M |
| Sales Growth (year/est) | 668.30% | -- | 1,665.50% | 13.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.83 | -0.83 | -0.82 | -0.91 |
| EPS Actual | -0.92 | -0.98 | -1.08 | -0.96 |
| Difference | -0.09 | -0.15 | -0.26 | -0.05 |
| Surprise % | -10.80% | -18.10% | -31.70% | -5.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.89 | -0.9 | -3.27 | -3.06 |
| 7 Days Ago | -0.92 | -0.94 | -3.25 | -3.03 |
| 30 Days Ago | -0.92 | -0.94 | -3.25 | -3.03 |
| 60 Days Ago | -0.81 | -0.93 | -3.52 | -3.25 |
| 90 Days Ago | -0.99 | -1 | -3.45 | -3.06 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | BBIO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 3.30% | -- | -- | 1.50% |
| Next Qtr. | 8.20% | -- | -- | 11.40% |
| Current Year | 17.20% | -- | -- | 5.20% |
| Next Year | 6.40% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 67.30% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | JP Morgan: Overweight to Overweight | 3/20/2024 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 3/19/2024 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 3/11/2024 |
| Maintains | Mizuho: Buy to Buy | 3/5/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/4/2024 |
| Maintains | Citigroup: Buy to Buy | 2/23/2024 |
Related Tickers
CYTK Cytokinetics, Incorporated
66.82
+1.91%
IMVT Immunovant, Inc.
28.80
+0.66%
ROIV Roivant Sciences Ltd.
10.90
-0.37%
DAWN Day One Biopharmaceuticals, Inc.
15.19
-8.71%
BHVN Biohaven Ltd.
38.72
-2.25%
APLS Apellis Pharmaceuticals, Inc.
49.93
+2.48%
CLRB Cellectar Biosciences, Inc.
3.0600
-1.61%
ALNY Alnylam Pharmaceuticals, Inc.
143.80
-1.55%
MLTX MoonLake Immunotherapeutics
42.43
-1.90%
BPMC Blueprint Medicines Corporation
92.26
-0.03%